Simplex Trading, LLC Cardiff Oncology, Inc. Transaction History

Simplex Trading, LLC

$2.81 Billion
Q3 2024

A detailed history of Simplex Trading, LLC transactions in Cardiff Oncology, Inc. stock. As of the latest transaction made, Simplex Trading, LLC holds 12,571 shares of CRDF stock, worth $34,821. This represents 0.0% of its overall portfolio holdings.

Number of Shares

12,571

Previous 24,645 48.99%

Holding current value

$34,821

Previous $54,000 38.89%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 08, 2024	SELL	$2.05 - $2.77 $24,751 - $33,444	-12,074 Reduced 48.99%	12,571 $33,000
Q2 2024 Jul 25, 2024	SELL	$2.22 - $5.89 $28,740 - $76,251	-12,946 Reduced 34.44%	24,645 $54,000
Q1 2024 Apr 25, 2024	BUY	$1.46 - $5.91 $54,882 - $222,162	37,591 New	37,591 $200,000
Q3 2023 Nov 01, 2023	BUY	$1.38 - $2.18 $21,460 - $33,901	15,551 New	15,551 $21,000
Q4 2022 Feb 02, 2023	SELL	$1.22 - $1.66 $14,158 - $19,264	-11,605 Reduced 52.5%	10,500 $14,000
Q3 2022 Nov 04, 2022	SELL	$1.54 - $3.21 $68,437 - $142,652	-44,440 Reduced 66.78%	22,105 $34,000
Q2 2022 Aug 03, 2022	BUY	$1.17 - $2.61 $46,844 - $104,499	40,038 Added 151.05%	66,545 $146,000
Q1 2022 May 02, 2022	SELL	$2.11 - $7.25 $70,957 - $243,810	-33,629 Reduced 55.92%	26,507 $65,000
Q4 2021 Feb 23, 2022	BUY	$5.18 - $7.24 $288,401 - $403,094	55,676 Added 1248.34%	60,136 $361,000
Q3 2021 Oct 28, 2021	SELL	$5.01 - $7.58 $1,733 - $2,622	-346 Reduced 7.2%	4,460 $29,000
Q2 2021 Aug 12, 2021	BUY	$6.65 - $10.04 $31,959 - $48,252	4,806 New	4,806 $31,000
Q1 2021 Apr 26, 2021	SELL	$9.1 - $19.57 $3,676 - $7,906	-404 Closed	0 $0
Q4 2020 Feb 02, 2021	BUY	$12.02 - $24.71 $4,856 - $9,982	404 New	404 $7,000

Others Institutions Holding CRDF

# of Institutions

Shares Held

12.3M

Call Options Held

813K

Put Options Held

91.1K

View Full List

About Cardiff Oncology, Inc.

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $120M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

More about CRDF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Simplex Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Simplex Trading, LLC with notifications on news.

Account

Simplex Trading, LLC Cardiff Oncology, Inc. Transaction History